GM
GMED.US Globus Medical
- Market cap
- USD 9.57B
- P/E
- 17.8x
- P/B
- 2.00x
- ROE
- 11.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GMED.US undervalued?
Graham numberGMED.US trades 25.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Globus Medical fundamental analysis
No fundamental analysis for Globus Medical yet.
Globus Medical stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Globus Medical
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction …
Full company profileGlobus Medical financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Globus Medical annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 564M | 636M | 713M | 785M | 789M | 958M | 1.02B | 1.57B | 2.52B | 2.94B | 3.08B |
| Gross Profit | 429M | 486M | 554M | 605M | 572M | 719M | 759M | 1.02B | 1.48B | 1.98B | 2.14B |
| Operating Income | 154M | 162M | 169M | 172M | 111M | 172M | 228M | 133M | 166M | 480M | 698M |
| EBITDA | 193M | 205M | 219M | 229M | 178M | 265M | 305M | 347M | 474M | 887M | 987M |
| Net Income | 104M | 107M | 156M | 155M | 102M | 149M | 190M | 123M | 103M | 538M | 556M |
| EPS | 1.08 | 1.10 | 1.54 | 1.52 | 1.01 | 1.44 | 1.85 | 1.07 | 0.75 | 3.92 | 4.09 |
| Balance Sheet | |||||||||||
| Total Assets | 928M | 1.08B | 1.30B | 1.53B | 1.68B | 1.96B | 2.08B | 5.09B | 5.25B | 5.30B | 5.53B |
| Total Liabilities | 95.6M | 111M | 115M | 130M | 173M | 216M | 230M | 1.09B | 1.07B | 730M | 732M |
| Shareholders' Equity | 832M | 968M | 1.19B | 1.40B | 1.51B | 1.74B | 1.85B | 4.00B | 4.18B | 4.57B | 4.80B |
| Cash & Short-term Investments | 290M | 374M | 340M | 311M | 427M | 443M | 446M | 518M | 890M | 557M | 517M |
| Total Debt | - | - | - | 2.48M | 4.80M | 5.05M | 6.01M | 520M | 537M | 119M | 108M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 172M | 160M | 182M | 172M | 199M | 276M | 178M | 243M | 521M | 753M | 903M |
| Capital Expenditure | 40.9M | 51.3M | 59.7M | 70.8M | 63.7M | 56.9M | 74.0M | 78.3M | 115M | 165M | 151M |
| Free Cash Flow | 131M | 108M | 122M | 101M | 135M | 219M | 104M | 165M | 405M | 589M | 752M |
| Ratios | |||||||||||
| ROE | 12.5% | 11.1% | 13.2% | 11.1% | 6.8% | 8.6% | 10.3% | 3.1% | 2.5% | 11.8% | 11.6% |
| ROA | 11.2% | 10.0% | 12.0% | 10.1% | 6.1% | 7.6% | 9.2% | 2.4% | 2.0% | 10.1% | 10.1% |
| Net Profit Margin | 18.5% | 16.9% | 21.9% | 19.8% | 13.0% | 15.6% | 18.6% | 7.8% | 4.1% | 18.3% | 18.0% |
| Debt to Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.13x | 0.13x | 0.03x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Globus Medical dividends
Globus Medical has not paid dividends in the last 9 fiscal years.
Who owns Globus Medical
- Insiders 0.75%
- Institutions 99.25%
- Public & others 0.00%
- Shares outstanding 110M
- Free float 109M
Top funds holding GMED.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 4.02M | 3.03% | +0.05% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.60M | 2.72% | +0.27% | Sep 2026 |
| Vanguard Small Cap Index | 2.53M | 1.91% | -2.72% | Sep 2026 |
| Janus Henderson Enterprise D | 2.31M | 1.74% | 0.00% | Sep 2026 |
| JPMorgan Mid Cap Value L | 1.62M | 1.22% | +0.71% | Sep 2026 |
| Swedbank Robur Aktiefond Pension | 1.52M | 1.15% | +1.55% | Oct 2026 |
| Allspring Special Mid Cap Value Inst | 1.41M | 1.06% | 0.00% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.41M | 1.06% | -5.62% | Sep 2026 |
| JHancock Disciplined Value Mid Cap I | 1.30M | 0.98% | -0.59% | Aug 2026 |
| Invesco Small Cap Value A | 1.13M | 0.85% | +5.11% | Sep 2026 |
| Janus Henderson Triton D | 1.11M | 0.84% | 0.00% | Sep 2026 |
| Invesco Value Opportunities A | 926K | 0.70% | +6.43% | Sep 2026 |
| State Street® SPDR® S&P MIDCAP 400® ETF | 827K | 0.62% | -0.22% | Sep 2026 |
| Janus Henderson Global Life Sciences D | 815K | 0.61% | +1.35% | Sep 2026 |
| Janus Global Life Science AUSD | 792K | 0.60% | +12.00% | Sep 2026 |
| Eaton Vance Atlanta Capital SMID-Cap I | 786K | 0.59% | 0.00% | Sep 2026 |
| Janus Henderson Glb Life Scn I2 USD | 771K | 0.58% | +8.72% | Aug 2026 |
| FullerThaler Behavioral Sm-Cp Gr R6 | 739K | 0.56% | +2.80% | Jun 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 673K | 0.51% | -0.26% | Oct 2026 |
| JPMorgan Mid Cap Equity I | 658K | 0.50% | +3.07% | Sep 2026 |
Top institutions holding GMED.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 10.8M | 8.05% | +2.95% | Jun 2026 |
| Jupiter Topco LLC | 8.20M | 6.11% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 5.11M | 3.80% | +1.49% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 4.99M | 3.72% | +2.36% | Jun 2026 |
| Amvescap Plc. | 4.31M | 3.21% | -0.16% | Jun 2026 |
| Kayne Anderson Rudnick Investment Management LLC | 4.28M | 3.19% | 0.00% | Jun 2026 |
| State Street Corp | 3.71M | 2.77% | +3.44% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 3.01M | 2.24% | +26.93% | Sep 2026 |
| OZ Management LLC | 3.00M | 2.23% | -1.90% | Jun 2026 |
| JPMorgan Chase & Co | 2.74M | 2.04% | +5.72% | Jun 2026 |
| Bank of Montreal | 2.43M | 1.81% | +5.13% | Jun 2026 |
| BMO Capital Markets Corp. | 2.43M | 1.81% | +5.13% | Jun 2026 |
| AllianceBernstein L.P. | 2.38M | 1.77% | +35.96% | Jun 2026 |
| Geode Capital Management, LLC | 2.15M | 1.60% | +1.94% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.78M | 1.33% | +57.36% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 1.72M | 1.28% | +88.04% | Jun 2026 |
| BTIM Corp | 1.64M | 1.22% | +4.44% | Sep 2026 |
| Allspring Global Investments Holdings, LLC | 1.57M | 1.17% | +267.18% | Jun 2026 |
| Boston Partners Global Investors, Inc | 1.55M | 1.16% | 0.00% | Jun 2026 |
| GW&K Investment Management, LLC | 1.45M | 1.08% | -2.78% | Jun 2026 |
Globus Medical company profile
- Company name
- Globus Medical
- Ticker
- GMED.US
- Exchange
- USA Stocks
- Listed since
- Aug 3, 2012
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 6,000
- Fiscal year end
- December
- Address
- 2560 General Armistead Avenue, Audubon, PA, United States, 19403-5214
- Phone
- 610 930 1800
- Website
- globusmedical.com
About Globus Medical
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Globus Medical management
5- Mr. David C. PaulCo-Founder & Executive Chairman · born 1967
- Mr. Keith W. PfeilCEO, President & Director · born 1979
- Mr. Kyle R. KlinSenior VP & CFO · born 1986
- Ms. Kelly G. Huller Esq.Executive VP, General Counsel & Corporate Secretary · born 1972
- Mr. Brian J. KearnsSenior Vice President of Business Development & Investor Relations · born 1967